528
Participants
Start Date
August 25, 2020
Primary Completion Date
June 30, 2025
Study Completion Date
December 31, 2025
TQB2450
TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Anlotinib
A multi-target receptor tyrosine kinase inhibitor.
Sunitinib
A multi-target receptor tyrosine kinase inhibitor.
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
China-Japan Friendship Hospital, Beijing
Peking Union Medical College Hospital, Beijing
Peking University First Hospital, Beijing
Beijing Cancer Hospital, Beijing
Peking University Third Hospital, Beijing
Chinese PLA General Hospital, Beijing
Liaoning Cancer Hospital & Institute, Shenyang
The Second Hospital of Dalian Medical University, Dalian
The First Hospital of Jilin University, Changchun
The Affiliated Tumor Hospital of Harbin Medical University, Harbin
Tenth People's Hospital of Tongji University, Shanghai
Shanghai General Hospital, Shanghai
The Affiliated Hospital of Nanjing University Medical School, Nanjing
Jiangsu Province Hospital, Nanjing
The Second Affiliated Hospital of Anhui Medical University, Hefei
Qilu Hospital of Shandong University, Jinan
Yantai Yuhuangding Hospital, Yantai
Tianjin Medical University Cancer Institute & Hospital, Tianjin
Second Hospital of Tianjin Medical University, Tianjin
Cancer Hospital of The University of Chinese Academy of Sciences, Hangzhou
The First Hospital of Jiaxing, Jiaxing
Jiangxi Cancer Hospital, Nanchang
The First Affiliated Hospital of Nanchang University, Nanchang
Fujian Provincial Hospital, Fuzhou
The First Affiliated Hospital of Fujian Medical University, Fuzhou
Chongqing University Cancer Hospital, Chongqing
The First Affiliated Hospital of the Chinese People's Liberation Army Army Medical University, Chongqing
The First Affiliated Hospital of Chongqing Medical University, Chongqing
Hunan Cancer Hospital, Changsha
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Sun Yat-sen of Cancer Center, Guangzhou
West China Hospital of Sichuan University, Chengdu
The Second Affiliated Hospital of Xi 'an Jiaotong University, Xi’an
The First Affiliated Hospital of PLA Air Force Military Medical University, Xi’an
First Hospital of Lanzhou University, Lanzhou
The Affiliated Hospital of Xinjiang Medical University, Ürümqi
The First Affiliated Hospital of Xinjiang Medical University, Ürümqi
First Affiliated Hospital,School of Medicine,Shihezi University, Shihezi
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY